PetMed Express Reports Wider Loss Amid Revenue Decline

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: Jun 02 2026

0mins

PETS+1.1%

Explore Agentic TradingLet AI Trade for You

Source: seekingalpha

Wider Loss Reported: PetMed Express reported a fiscal fourth-quarter loss of $0.19 per share, which, while an improvement from last year's $0.56 loss, still missed expectations by $0.01, indicating ongoing profitability challenges for the company.
Significant Revenue Decline: The company's net sales fell by 15.6% to $42.8 million, primarily driven by a decrease in prescription medication sales, a trend that could negatively impact future market share and competitive positioning.
Deteriorating Cash Flow: By fiscal year-end, PetMed Express's cash and cash equivalents plummeted nearly two-thirds to $21.4 million, and net cash from operating activities swung to a $28.4 million outflow from a $4.7 million inflow a year earlier, reflecting increasing liquidity risks for the company.
Rejection of Acquisition Offers: Despite receiving a $4.25 per share acquisition offer from Cardone Ventures, PetMed Express has opted to continue operating as an independent publicly traded company, a decision that may affect investor confidence in the company's future prospects.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PETS?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PETS

About PETS

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

PetMed Express Reports Financial and Operational Improvements

Jun 03 2026Yahoo Finance

Regulatory Compliance Restored: PetMed Express successfully regained critical regulatory compliance and improved internal controls in fiscal year 2026, remediating three previously disclosed material weaknesses, thereby laying a foundation for future sustainable growth.
Sales Fluctuations: While the fourth quarter net sales marked the first sequential increase since fiscal year 2024, the overall net sales for the year declined by 21.1%, indicating that the ongoing decrease in prescription medication sales negatively impacted total revenue.
Cost Reduction Success: The company exited underperforming vendor relationships, yielding approximately $6.1 million in annualized savings, which not only improved cost structure but also enhanced operational efficiency and customer experience.
Clear Strategic Direction: Looking ahead to fiscal year 2027, PetMed Express plans to focus on operational excellence, customer retention, and market expansion, aiming to drive long-term sustainable shareholder value through B2B relationships and improvements in technology and infrastructure.

PetMed Express (PETS) Q4 2026 Earnings Transcript

Jun 03 2026NASDAQ.COM

PetMed Express Q4 Fiscal 2026 Earnings Call Insights

Jun 02 2026seekingalpha

Sales Decline: PetMed Express reported net sales of $179 million for fiscal year 2026, reflecting a 21.1% year-over-year decline primarily due to reduced prescription medication sales, although the revenue decline slowed to 15.6% in Q4 compared to the previous year.
Cost Reduction Success: The company made significant progress in cost-cutting efforts, exiting underperforming vendor relationships in the second half of the year, which is expected to yield approximately $6.1 million in annualized savings, indicating effective financial management.
Technology Infrastructure Upgrade: The successful implementation of a new ERP system, fraud prevention system, and call center technology has strengthened operational capabilities, aiming to enhance customer experience and significantly reduce operational risks moving forward.
Independent Operation Decision: The Board opted not to proceed with two unsolicited acquisition proposals priced between $4 and $4.25 per share, choosing to continue operating as an independent publicly traded company, which reflects confidence in the company's long-term strategy.